Page 3 - Johnson Enterprise Innovation Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article LEXINGTON, Mass., April 12, 2021 /PRNewswire/  Pulmatrix, Inc. (NASDAQ: PULM), is re-issuing this press release solely to correct inadvertent typographical errors under the heading Updated PUR1800 Program Guidance which incorrectly noted that Pulmatrix plans to initiate a PUR1800 Phase 2 proof-of-concept efficacy study for the treatment of AECOPD in 2021. This study is not expected to commence until 2022 All other data and disclosure remain unchanged. The corrected press release reads in its entirety as follows: LEXINGTON, Mass., April 12, 2021 – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced it will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following Johnsons & Johnson s Enterprise Innovation s decision to terminate the

Timothy mccarthyTed raadJohnson enterprise innovation incPulmatrix incProgram guidanceCompany quarterly reports on formEnterprise innovationChief executive officerPrivate securities litigation reform actQuarterly reportsJohnson enterprise innovationதீமோத்தேயு ம்க்கார்தீடெட் ராட்ஜான்சன் நிறுவன கண்டுபிடிப்பு இன்க்ப்ரோக்ர்யாம் வழிகாட்டல்நிறுவனம் காலாண்டு அறிக்கைகள் ஆன் வடிவம்